Treatment Outcomes of Recommended First-Line Antiretroviral Regimens in Resource-Limited Clinics

摘要: BACKGROUND: Although used globally little data exist on the efficacy of nevirapine (NVP) in combination with tenofovir (TDF)/emtricitabine or lamivudine (XTC) and no large randomized prospective control trials exists comparing this efavirenz (EFV)/TDF/(XTC). METHODS: As part AIDSRelief program a retrospective review patient medical chart information along cross-sectional viral load adherence measurement was conducted between 2004 2009. An on-treatment analysis excluded patients who died transferred out care were lost to follow-up. A switch antiretrovirals for any reason considered failure intent-to-treat analysis. Patients only clinically relevant reasons switching such as toxicity adverse effects clinical/immunological follow-up death failures modified-intent-to-treat Step-wise multiple regression identify variables that associated suppression. RESULTS: random sample 3862 met criteria included In older age (P < 0.004) baseline CD4 <100 cells per cubic millimeter 0.021) most significant impacting load. TDF/XTC/EFV achieved higher rates suppression compared TDF/XTC/NVP azidothymidine (AZT)/lamivudine (3TC)/NVP. CONCLUSION: Our show had better outcomes than AZT/3TC/EFV AZT/3TC/NVP. High virologic seen regimen are consistent previous studies indicate need increase use HIV programs promote sustainable over time.